ReviewPharmaceuticals (Basel, Switzerland)2022
CRISPR-Cas System: A Tool to Eliminate Drug-Resistant Gram-Negative Bacteria.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Engineering the Gut Microbiome: Emerging Genome-Editing Strategies and Therapeutic Applications.Microorganisms · 2026Review
- A machine learning model for the early prediction of Gram-negative bloodstream infection in ICU patients.BMC medical informatics and decision making · 2026Article
- Applications and Challenges of CRISPR-Cas Technology for the Detection of Antimicrobial Resistance Genes.Infection and drug resistance · 2026Review
- Recent Advances and Future Perspectives in the Detection of Carbapenem-ResistantInfection and drug resistance · 2026Review
- Research advances in the application of microfluidic chip technology for rapid detection of antibiotic-resistant bacteria.Frontiers in cellular and infection microbiology · 2026Review
- Avian PathogenicVeterinary sciences · 2025Review
- Unveiling the Mechanisms of Bacterial Resistance and Countermeasures.Pathogens (Basel, Switzerland) · 2025Review
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antibiotic-ResistantMicroorganisms · 2025Review
- Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review.Tropical medicine and health · 2025Review
- From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance-a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14.Heliyon · 2025Review
- Harnessing bacterial immunity: CRISPR-Cas system as a versatile tool in combating pathogens and revolutionizing medicine.Frontiers in cellular and infection microbiology · 2025Review
- Innovative Therapies: A Major Breakthrough in Combating Multi-Drugresistant Bacterial Infections Using Mixture Design and Multi-Objective Optimization with NSGA-II Algorithm.Current topics in medicinal chemistry · 2025Article
- Biochemistry and Future Perspectives of Antibiotic Resistance: An Eye on Active Natural Products.Antibiotics (Basel, Switzerland) · 2024Review
- Design, potential and limitations of conjugation-based antibacterial strategies.Microbial biotechnology · 2024Review
- Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.Heliyon · 2024Review
- Recent advances in gene-editing approaches for tackling antibiotic resistance threats: a review.Frontiers in cellular and infection microbiology · 2024Review
- Recent Advances in Understanding the Molecular Mechanisms of Multidrug Resistance and Novel Approaches of CRISPR/Cas9-Based Genome-Editing to Combat This Health Emergency.International journal of nanomedicine · 2024Review
- Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update.Infectious disorders drug targets · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapidly emerging drug-resistant superbugs, especially Gram-negative bacteria, pose a serious threat to healthcare systems all over the globe. Newer strategies are being developed to detect and overcome the arsenal of weapons that these bacteria possess. The development of antibiotics is time-consuming and may not provide full proof of action on evolving drug-resistant pathogens. The clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR/Cas) systems are promising in curbing drug-resistant bacteria. This review focuses on the pathogenesis of Gram-negative bacteria, emergence of antimicrobial drug resistance, and their treatment failures. It also draws attention to the present status of the CRISPR-Cas system in diagnosisand treatment of Gram-negative bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.